User login
Key clinical point: Rimegepant was effective and had favourable safety and tolerability profiles in the preventive treatment of migraine.
Major finding: Rimegepant was superior to placebo in terms of change in the mean number of migraine days per month during weeks 9-12 (−4.3 days vs. −3.5 days; least squares mean difference, −0.8 days; P = .0099). Adverse events were reported by 133 of the patients who received rimegepant and 133 participants in the placebo group.
Study details: A multicentre, phase 2/3, randomised, double-blind, placebo-controlled trial of 695 participants randomly assigned to receive oral rimegepant 75 mg (n = 348) or matching placebo (n=347) every other day for 12 weeks. The safety analysis included 741 participants, who received at least one dose of study medication.
Disclosures: The study was funded by Biohaven Pharmaceuticals. Some study investigators reported owning stock in, being an employee of, receiving support/grant from Biohaven Pharmaceuticals.
Source: Croop R et al. Lancet. 2020 Dec 15. doi: 10.1016/S0140-6736(20)32544-7.
Key clinical point: Rimegepant was effective and had favourable safety and tolerability profiles in the preventive treatment of migraine.
Major finding: Rimegepant was superior to placebo in terms of change in the mean number of migraine days per month during weeks 9-12 (−4.3 days vs. −3.5 days; least squares mean difference, −0.8 days; P = .0099). Adverse events were reported by 133 of the patients who received rimegepant and 133 participants in the placebo group.
Study details: A multicentre, phase 2/3, randomised, double-blind, placebo-controlled trial of 695 participants randomly assigned to receive oral rimegepant 75 mg (n = 348) or matching placebo (n=347) every other day for 12 weeks. The safety analysis included 741 participants, who received at least one dose of study medication.
Disclosures: The study was funded by Biohaven Pharmaceuticals. Some study investigators reported owning stock in, being an employee of, receiving support/grant from Biohaven Pharmaceuticals.
Source: Croop R et al. Lancet. 2020 Dec 15. doi: 10.1016/S0140-6736(20)32544-7.
Key clinical point: Rimegepant was effective and had favourable safety and tolerability profiles in the preventive treatment of migraine.
Major finding: Rimegepant was superior to placebo in terms of change in the mean number of migraine days per month during weeks 9-12 (−4.3 days vs. −3.5 days; least squares mean difference, −0.8 days; P = .0099). Adverse events were reported by 133 of the patients who received rimegepant and 133 participants in the placebo group.
Study details: A multicentre, phase 2/3, randomised, double-blind, placebo-controlled trial of 695 participants randomly assigned to receive oral rimegepant 75 mg (n = 348) or matching placebo (n=347) every other day for 12 weeks. The safety analysis included 741 participants, who received at least one dose of study medication.
Disclosures: The study was funded by Biohaven Pharmaceuticals. Some study investigators reported owning stock in, being an employee of, receiving support/grant from Biohaven Pharmaceuticals.
Source: Croop R et al. Lancet. 2020 Dec 15. doi: 10.1016/S0140-6736(20)32544-7.